MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1002/acr2.70132

Медицинская библиотека · ACR open rheumatology · 2025

Characteristics Associated With EuroLupus Versus Modified National Institutes of Health Cyclophosphamide Regimen Use in Children and Young Adults With Lupus Nephritis.

Wang Christine S, Sadun Rebecca E, Zhou Wenru, Miller Kristen R, Ardoin Stacy P, Bearer Christine, Hause Emily, Hui-Yuen Joyce, Ling Nicole, Pereira Maria, Riebschleger Meredith, Rouster-Stevens Kelly, Sarkissian Aliese, Shalen Julia, Soulsby William Daniel, Twilt Marinka, Wu Eveline Y, Lewandowski Laura B, Wenderfer Scott E, Cooper Jennifer C, Childhood Arthritis and Rheumatology Research Alliance Lupus Nephritis Working Group

СтатьяПеревод пока не подготовлен

Аннотация

OBJECTIVE

To determine the demographic and clinical characteristics associated with use of the EuroLupus or modified National Institutes of Health (NIH) cyclophosphamide (CYC) regimen for treatment of lupus nephritis (LN) at North American pediatric centers.

METHODS

A retrospective cohort study was conducted at 11 North American centers. Patients <22 years of age with active LN treated with CYC using the EuroLupus or NIH regimen between July 2014 and June 2021 were included. Data were extracted via electronic medical record review. Demographic and clinical characteristics were compared at CYC initiation. A multivariable generalized estimating equation with logit link was fit to model EuroLupus use. An exchangeable correlation structure was used to account for correlation within centers. Independent variables were chosen using elastic net regression.

RESULTS

The cohort consisted of 191 patients (85 EuroLupus, 106 NIH) with a median age of 15.3 years at CYC initiation. In multivariable analysis, characteristics significantly associated with EuroLupus regimen use (vs NIH regimen use) included more recent year of CYC initiation, longer disease duration, Hispanic ethnicity and Asian race (as compared to Black), previous CYC treatment, renal impairment (dialysis or mild kidney impairment), and absence of neuropsychiatric involvement.

CONCLUSION

For children and young adults with LN requiring CYC, use of the EuroLupus regimen increased over time and is associated with demographic and clinical factors such as race or Hispanic ethnicity, renal impairment, and absence of neuropsychiatric involvement. The differences in regimen use with severe renal impairment and neuropsychiatric lupus highlight areas for future study in CYC dosing.

Для цитирования: Wang Christine S, Sadun Rebecca E, Zhou Wenru, Miller Kristen R, Ardoin Stacy P, Bearer Christine, Hause Emily, Hui-Yuen Joyce, Ling Nicole, Pereira Maria, Riebschleger Meredith, Rouster-Stevens Kelly, Sarkissian Aliese, Shalen Julia, Soulsby William Daniel, Twilt Marinka, Wu Eveline Y, Lewandowski Laura B, Wenderfer Scott E, Cooper Jennifer C, Childhood Arthritis and Rheumatology Research Alliance Lupus Nephritis Working Group. Characteristics Associated With EuroLupus Versus Modified National Institutes of Health Cyclophosphamide Regimen Use in Children and Young Adults With Lupus Nephritis.. ACR open rheumatology. 2025. DOI: 10.1002/acr2.70132.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.